Cempra (CEMP -0.2%) fails to get any reaction out of Jefferies' initiating coverage today with a Buy rating and $10 price target. The firm cites optimism over its pipeline, saying that its lead drug solithromycin is the key value driver. However, the company has limited capital, which has impacted its ability to conduct Phase 3 trials in an expedited manner. It will likely need to secure additional financing to further advance its programs, leaving the the stock with a potential dilutive overhang.
Cempra (CEMP -0.2%) fails to get any reaction out of Jefferies' initiating coverage today with a...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs